Published in Nat Rev Immunol on August 01, 2005
Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2006) 8.90
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun (2006) 1.72
The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol (2012) 1.39
Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb) (2011) 1.25
The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol (2013) 1.15
Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin Microbiol Rev (2010) 1.13
Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med (2010) 1.03
Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge. Mucosal Immunol (2015) 0.97
A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis. Clin Exp Immunol (2006) 0.95
Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology (2006) 0.91
Prime-boost approaches to tuberculosis vaccine development. Expert Rev Vaccines (2012) 0.91
Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients. Mol Cell Proteomics (2009) 0.89
Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet Vaccines Ther (2007) 0.88
Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients. BMC Infect Dis (2014) 0.88
Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis. J Biol Chem (2014) 0.87
Helminth coinfection does not affect therapeutic effect of a DNA vaccine in mice harboring tuberculosis. PLoS Negl Trop Dis (2010) 0.87
Unfolding the relationship between secreted molecular chaperones and macrophage activation states. Cell Stress Chaperones (2008) 0.86
Endocytosis of Mycobacterium tuberculosis heat shock protein 60 is required to induce interleukin-10 production in macrophages. J Biol Chem (2013) 0.86
Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion. Infect Immun (2009) 0.86
A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol (2013) 0.86
Interaction of Pattern Recognition Receptors with Mycobacterium Tuberculosis. J Clin Immunol (2014) 0.85
Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology (2007) 0.84
IL-12 and IL-27 regulate the phagolysosomal pathway in mycobacteria-infected human macrophages. Cell Commun Signal (2014) 0.83
An important role of prostanoid receptor EP2 in host resistance to Mycobacterium tuberculosis infection in mice. J Infect Dis (2012) 0.82
Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model. J Infect Dis (2014) 0.82
IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PLoS One (2013) 0.81
Lower levels of interleukin-12 precede the development of tuberculosis among HIV-infected women. Cytokine (2011) 0.81
Increased pleural soluble fas ligand (sFasL) levels in tuberculosis pleurisy and its relation with T-helper type 1 cytokines. Lung (2008) 0.78
Dynamics of adrenal steroids are related to variations in Th1 and Treg populations during Mycobacterium tuberculosis infection in HIV positive persons. PLoS One (2012) 0.78
Immunological mechanisms by which concomitant helminth infections predispose to the development of human tuberculosis. Korean J Parasitol (2012) 0.77
Impaired gamma interferon response to Mycobacterium vaccae antigens in patients with cavitary pulmonary tuberculosis. Clin Vaccine Immunol (2008) 0.77
Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency. Clin Exp Immunol (2015) 0.76
LASID Meeting 2015. J Clin Immunol (2015) 0.75
A dynamic analysis of tuberculosis dissemination to improve control and surveillance. PLoS One (2010) 0.75
Torticollis in mice intravenously infected with Mycobacterium tuberculosis. J Am Assoc Lab Anim Sci (2011) 0.75
Effectiveness of the First Dose of BCG against Tuberculosis among HIV-Infected, Predominantly Immunodeficient Children. Biomed Res Int (2015) 0.75
The use of Quantiferon-TB gold in-tube test in screening latent tuberculosis among Saudi Arabia dialysis patients. Ann Thorac Med (2015) 0.75
A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice. Vaccine (2017) 0.75
Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet (2010) 10.21
Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques (2004) 6.42
Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med (2011) 5.25
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis (2010) 5.14
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet (2010) 4.95
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet (2010) 4.71
Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Lancet (2009) 4.53
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2009) 4.14
T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis (2007) 3.96
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis (2013) 3.12
Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis (2012) 3.09
Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet (2002) 2.92
New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn (2006) 2.89
Immunological biomarkers of tuberculosis. Nat Rev Immunol (2011) 2.88
Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet (2012) 2.83
Supervised and unsupervised self-testing for HIV in high- and low-risk populations: a systematic review. PLoS Med (2013) 2.69
Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ (2008) 2.66
Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. Lancet (2003) 2.64
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J (2012) 2.61
Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med (2009) 2.55
Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J (2012) 2.45
Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev (2014) 2.43
Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. PLoS One (2011) 2.40
Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS (2005) 2.38
Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One (2009) 2.34
Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis (2012) 2.29
High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med (2010) 2.23
Progress towards improved tuberculosis diagnostics for developing countries. Lancet (2006) 2.16
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn (2006) 2.16
Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol (2011) 2.07
What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One (2013) 2.05
Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis (2013) 2.05
Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One (2010) 2.03
Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol (2006) 1.99
Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy : pathogenesis, clinical manifestations and management. Drugs (2008) 1.95
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
The use of an automated quantitative polymerase chain reaction (Xpert MTB/RIF) to predict the sputum smear status of tuberculosis patients. Clin Infect Dis (2011) 1.88
Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol (2006) 1.76
Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med (2010) 1.73
Lung remodeling in pulmonary tuberculosis. J Infect Dis (2005) 1.71
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med (2014) 1.69
Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Eur Respir J (2011) 1.68
Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLoS Med (2013) 1.66
Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid. Thorax (2013) 1.64
IL-4 in tuberculosis: implications for vaccine design. Trends Immunol (2004) 1.63
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis (2013) 1.62
Reversing the tide of the UK tuberculosis epidemic. Lancet (2013) 1.61
BCG: the story continues. Lancet (2005) 1.55
HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med (2009) 1.54
Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis (2013) 1.49
Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol (2004) 1.48
TB diagnostic tests: how do we figure out their costs? Expert Rev Anti Infect Ther (2009) 1.47
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis (2012) 1.46
Will an unsupervised self-testing strategy for HIV work in health care workers of South Africa? A cross sectional pilot feasibility study. PLoS One (2013) 1.44
Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Lancet (2003) 1.43
Tuberculosis in the UK--time to regain control. BMJ (2011) 1.43
Identification of Pneumocystis carinii DNA by polymerase chain reaction in necropsy lung samples from children dying of respiratory tract illnesses. J Pediatr (2002) 1.42
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2010) 1.41
Lethal interaction: the colliding epidemics of tobacco and tuberculosis. Expert Rev Anti Infect Ther (2007) 1.41
Tuberculosis in prisons in sub-Saharan Africa--the need for improved health services, surveillance and control. Tuberculosis (Edinb) (2011) 1.40
New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med (2011) 1.40
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis (2013) 1.39
The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS One (2012) 1.38
Differential susceptibility of PCR reactions to inhibitors: an important and unrecognised phenomenon. BMC Res Notes (2008) 1.37
Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting. PLoS One (2009) 1.34
Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. J Immunol Methods (2005) 1.29
Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis (2012) 1.28
Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med (2010) 1.23
Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am (2010) 1.23
Tuberculosis control is crucial to achieve the MDGs. Lancet (2010) 1.22
Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med (2014) 1.20
Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS One (2011) 1.19
The resurgence of disease: social and historical perspectives on the 'new' tuberculosis. Soc Sci Med (2002) 1.19
How great is the risk of Middle East respiratory syndrome coronavirus to the global population? Expert Rev Anti Infect Ther (2013) 1.19
Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr Opin HIV AIDS (2012) 1.18
Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar. Clin Vaccine Immunol (2010) 1.17
Correlation of mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary load in a high burden setting. PLoS One (2012) 1.16
Progress and challenges in childhood tuberculosis. Lancet Infect Dis (2013) 1.16
Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons? PLoS One (2013) 1.16
Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology (2004) 1.15
Thoracic empyema: current opinions in medical and surgical management. Curr Opin Pulm Med (2010) 1.14
Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One (2013) 1.12
Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health (2010) 1.11
The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev (2014) 1.11
Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop Med Int Health (2010) 1.10
Tuberculosis in prisons in sub-Saharan Africa--a potential time bomb. S Afr Med J (2011) 1.10
In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis. Am J Respir Crit Care Med (2005) 1.10
High rates of congenital cytomegalovirus infection linked with maternal HIV infection among neonatal admissions at a large referral center in sub-Saharan Africa. Clin Infect Dis (2013) 1.10
Biomarkers for tuberculosis disease status and diagnosis. Curr Opin Pulm Med (2009) 1.09
Utility of a novel lipoarabinomannan assay for the diagnosis of tuberculous meningitis in a resource-poor high-HIV prevalence setting. Cerebrospinal Fluid Res (2009) 1.08
Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa. Int J Gynaecol Obstet (2010) 1.08